{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:44:41Z","timestamp":1791247481759,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ajpc.2026.101442","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:39:36Z","timestamp":1771223976000},"page":"101442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The emerging role of CETP inhibition in the prevention of Alzheimer's disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Michael H","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathijs","family":"de Kleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ajpc.2026.101442_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030780","article-title":"Cardiovascular disease and Alzheimer's disease: the heart\u2013brain axis","volume":"12","author":"Saeed","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101442_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100394","article-title":"Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease","volume":"13","author":"Davidson","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101442_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70565","article-title":"Cognitive impairment and p-tau217 are higher in a vascular patient cohort","volume":"21","author":"French","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ajpc.2026.101442_bib0004","series-title":"Presented at: Clinical Trials in Alzheimer's Disease (CTAD)","article-title":"From real-world data to clinical trials: the case for investigating semaglutide in Alzheimer's disease","author":"Johannsen","year":"2025"},{"key":"10.1016\/j.ajpc.2026.101442_bib0005","series-title":"Presented at: Clinical Trials in Alzheimer's Disease (CTAD)","article-title":"EVOKE and EVOKE+: two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage Alzheimer's disease","author":"Cummings","year":"2025"},{"key":"10.1016\/j.ajpc.2026.101442_bib0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fnagi.2015.00119","article-title":"Oxidized cholesterol as the driving force behind the development of Alzheimer's disease","volume":"7","author":"Gamba","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.ajpc.2026.101442_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101442_bib0008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13024-023-00671-y","article-title":"Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia","volume":"18","author":"Poliakova","year":"2023","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.ajpc.2026.101442_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1430465","article-title":"New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease","volume":"18","author":"Cao","year":"2024","journal-title":"Front Neurosci"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101442_bib0010","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4103\/NRR.NRR-D-24-01412","article-title":"Regulation of synaptic function and lipid metabolism","volume":"21","author":"Zhang","year":"2026","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.ajpc.2026.101442_bib0011","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41398-022-02024-7","article-title":"Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype?","volume":"12","author":"Anastacio","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.ajpc.2026.101442_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.630502","article-title":"APOE and Alzheimer's disease: from lipid transport to physiopathology and therapeutics","volume":"15","author":"Husain","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.ajpc.2026.101442_bib0013","series-title":"Apolipoprotein E","article-title":"APOE and oxidative stress","author":"Correas","year":"2025"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101442_bib0014","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.tcb.2023.09.004","article-title":"The cell biology of APOE in the brain","volume":"34","author":"Windham","year":"2024","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.ajpc.2026.101442_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ajpc.2026.101442_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1535280","article-title":"Multi-functional role of apolipoprotein E in neurodegenerative diseases","volume":"17","author":"Islam","year":"2025","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.ajpc.2026.101442_bib0017","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41591-025-03835-z","article-title":"APOE4 carriers share immune-related proteomic changes across neurodegenerative diseases","volume":"31","author":"Shvetcov","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101442_bib0018","doi-asserted-by":"crossref","first-page":"100865","DOI":"10.1016\/j.jlr.2025.100865","article-title":"Cerebrospinal fluid lipoprotein mediated cholesterol delivery to neurons is impaired in Alzhimer\u2019s disease and involves APOE4","volume":"66","author":"Borr\u00e0s","year":"2025","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101442_bib0019","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/s12276-024-01273-4","article-title":"Cholesterol imbalance and neurotransmission defects in neurodegeneration","volume":"56","author":"Shin","year":"2024","journal-title":"Exp Mol Med"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101442_bib0020","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s10571-023-01365-1","article-title":"Roles of ApoE4 on the pathogenesis in Alzheimer's disease and the potential therapeutic approaches","volume":"43","author":"Sun","year":"2023","journal-title":"Cell Mol Neurobiol"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101442_bib0021","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3390\/antiox13121462","article-title":"Role of oxidative stress in blood\u2013brain barrier disruption and neurodegenerative diseases","volume":"13","author":"Kim","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.ajpc.2026.101442_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-025-01365-z","article-title":"The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases","author":"Feringa","year":"2025","journal-title":"Nat Metab"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101442_bib0023","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/jamaneurol.2019.0648","article-title":"Association of early-onset Alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of APOB","volume":"76","author":"Wingo","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ajpc.2026.101442_bib0024","article-title":"Protective ApoE variants support neuronal function by effluxing oxidized phospholipids","author":"Ralhan","year":"2025","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101442_bib0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/jamaneurol.2019.0648","article-title":"Association of early-onset Alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of APOB","volume":"76","author":"Wingo","year":"2019","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101442_bib0026","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.stem.2022.07.005","article-title":"Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity","volume":"29","author":"Victor","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"14","key":"10.1016\/j.ajpc.2026.101442_bib0027","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.3390\/ijms26146940","article-title":"APOE genotype-stratified meta-analysis of cognitive decline reveals novel loci for language and global cognitive function in older adults","volume":"26","author":"Acharya","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101442_bib0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.29245\/2572-9411\/2016\/2.1032","article-title":"DDHD domain-containing lipases: targets for the treatment of rare diseases","volume":"1","author":"Yadav","year":"2016","journal-title":"J Rare Dis Res Treat"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101442_bib0029","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jama.2009.1988","article-title":"Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101442_bib0030","first-page":"984","article-title":"Serum concentrations of apolipoprotein A-I (ApoA-I) and Alzheimer's disease: systematic review and meta-analysis","volume":"11","author":"Zuin","year":"2021","journal-title":"Diagn (Basel)"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101442_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100260","article-title":"The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain","volume":"63","author":"Oestereich","year":"2022","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101442_bib0032","doi-asserted-by":"crossref","first-page":"911","DOI":"10.5551\/jat.RV22037","article-title":"Cholesterol ester transfer protein deficiency and hyperalphalipoproteinemia","volume":"32","author":"Inazu","year":"2025","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ajpc.2026.101442_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70638","article-title":"Cholesterol-lowering drug targets reduce risk of dementia: mendelian randomization and meta-analyses of 1 million individuals","volume":"21","author":"Nordestgaard","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ajpc.2026.101442_bib0034","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13195-024-01594-6","article-title":"Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis","volume":"16","author":"Schmidt","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.ajpc.2026.101442_bib0035","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101442_bib0036","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease","volume":"74","author":"Feldman","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101442_bib0037","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function","volume":"80","author":"Rosoff","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2026.101442_bib0038","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/01.ATV.0000205595.19612.c9","article-title":"Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis","volume":"26","author":"Klerx","year":"2006","journal-title":"Arter Thromb Vasc Biol"},{"issue":"7806","key":"10.1016\/j.ajpc.2026.101442_bib0039","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"Blood\u2013brain barrier breakdown in the aging human hippocampus","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ajpc.2026.101442_bib0040","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3390\/cells12212512","article-title":"Detrimental effects of ApoE \u03b54 on blood\u2013brain barrier integrity and their potential implications on the pathogenesis of Alzheimer's disease","volume":"12","author":"Kirchner","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ajpc.2026.101442_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neurobiolaging.2024.04.003","article-title":"Association of APOE genotype with blood\u2013brain barrier permeability in neurodegenerative disorders","volume":"140","author":"Libri","year":"2024","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.ajpc.2026.101442_bib0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12987-024-00580-2","article-title":"Shusta EV. iPSC-derived blood\u2013brain barrier modeling reveals APOE isoform-dependent interactions with amyloid beta","volume":"21","author":"Ding","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ajpc.2026.101442_bib0043","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.3390\/ijms24054403","article-title":"Lipids at the nexus between cerebrovascular disease and vascular dementia: the impact of HDL-cholesterol and ceramides","volume":"24","author":"Sergi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.ajpc.2026.101442_bib0044","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.3390\/ijms26167908","article-title":"Apolipoprotein a (ApoA) in neurological disorders: connections and insights","volume":"26","author":"Rajha","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpc.2026.101442_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.700847","article-title":"Understanding the exchange of systemic HDL particles into the brain and vascular cells has diagnostic and therapeutic implications for neurodegenerative diseases","volume":"12","author":"Van Valkenburgh","year":"2021","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101442_bib0046","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neuron.2023.10.023","article-title":"Amelioration of tau and ApoE4-linked glial lipid accumulation and neurodegeneration with LXR agonist","volume":"112","author":"Litvinchuk","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.ajpc.2026.101442_bib0047","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13195-019-0497-9","article-title":"ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP\/PS1 mice","volume":"11","author":"Button","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101442_bib0048","first-page":"790","article-title":"The role of APOA-1 in Alzheimer's disease: bridging peripheral tissues and the central nervous system","volume":"18","author":"Xie","year":"2025","journal-title":"Pharm (Basel)"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101442_bib0049","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3390\/ijms26031380","article-title":"Molecular simulation of the binding of amyloid beta to apolipoprotein a-i in high-density lipoproteins","volume":"26","author":"Malajczuk","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101442_bib0050","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","article-title":"Central nervous system lipoproteins","volume":"36","author":"Mahley","year":"2016","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ajpc.2026.101442_bib0051","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.3390\/ijms26167908","article-title":"Apolipoprotein a (ApoA) in neurological disorders: connections and insights","volume":"26","author":"Rajha","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpc.2026.101442_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119560","article-title":"Obicetrapib significantly increases plasma and high-density lipoprotein (HDL) levels of lipophilic antioxidants","volume":"407","author":"Niesor","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2026.101442_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119512","article-title":"Low-dose obicetrapib significantly increases concentrations of lipophilic antioxidants, APOE, and S1P in HDL subfractions","volume":"407","author":"Niesor","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2026.101442_bib0054","first-page":"1","article-title":"Lutein from chicken eggs prevents amyloid \u03b2-peptide aggregation in vitro and amyloid \u03b2-induced inflammation in human macrophages (THP-1)","volume":"4","author":"Matsui","year":"2024","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101442_bib0055","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1471-4159.2004.02373.x","article-title":"Uptake and transport of high-density lipoprotein (HDL) and HDL-associated \u03b1-tocopherol by an in vitro blood-brain barrier model","volume":"89","author":"Balzas","year":"2004","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101442_bib0056","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/antiox10020223","article-title":"Carotenoids and cognitive outcomes: a meta-analysis of randomized intervention trials","volume":"10","author":"Davinelli","year":"2021","journal-title":"Antioxidants"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101442_bib0057","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.12380","article-title":"Tolerability, pharmacokinetics, and pharmacodynamics of TA-8995, a selective CETP inhibitor, in healthy subjects","volume":"78","author":"Ford","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajpc.2026.101442_bib0058","unstructured":"NewAmsterdam Pharma. Data on file. Proof-of-concept, open-label study in patients with early Alzheimer's disease. ClinicalTrials.gov Identifier: NCT05161715. 2023."},{"key":"10.1016\/j.ajpc.2026.101442_bib0059","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidemia (TULIP): a randomized, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2026.101442_bib0060","first-page":"159","article-title":"Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases","volume":"1","author":"Pikuleva","year":"2021","journal-title":"Explor Neuroprot Ther"},{"key":"10.1016\/j.ajpc.2026.101442_bib0061","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ajpc.2026.101442_bib0062","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of obicetrapib on major adverse cardiovascular events in high-risk patients: a pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101442_bib0063","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12987-025-00721-1","article-title":"Mechanisms of high-density lipoprotein in regulating blood-brain barrier function: insights and implications","volume":"22","author":"Zhu","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ajpc.2026.101442_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70662","article-title":"Trailblazer-ALZ 3: a randomized, double-blind study of donanemab in early preclinical Alzheimer's disease","volume":"21","author":"Yaari","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ajpc.2026.101442_bib0065","article-title":"Early Alzheimer's Disease: Developing Drugs for Treatment","year":"2018","journal-title":"Guid Ind"},{"key":"10.1016\/j.ajpc.2026.101442_bib0066","article-title":"Prevalence of Alzheimer's disease pathology in the community","author":"Aarsland","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ajpc.2026.101442_bib0067","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1474-4422(23)00508-2","article-title":"A chance to prevent Alzheimer's disease sooner than you think","volume":"23","author":"Reiman","year":"2024","journal-title":"Lancet Neurol"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266666772600036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266666772600036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:38:01Z","timestamp":1779694681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266666772600036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":67,"alternative-id":["S266666772600036X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101442","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of CETP inhibition in the prevention of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101442"}}